REFERENCE TO RELATED APPLICATION 0001 This application is related to and claims the benefit of U.S. Provisional Application Ser. No. 60/470,790 filed on May 15, 2003.

BACKGROUND OF THE INVENTION 0002 1. Field of the Invention 0003 This invention relates to cosmetic and pharmaceutical compositions containing at least one oxy group-bearing aromatic aldehyde in combination with at least one additional cosmetically or pharmaceutically effective agent, and their use to treat cosmetic or pharmaceutical conditions. More particularly it concerns such combinations in cosmetic compositions and in topical pharmaceutical compositions. 0004 2. State of the Art 0005 Aromatic aldehydes are a known class of materials. They commonly find use as chemical intermediates. Some aromatic aldehydes are components of natural products.

SUMMARY OF THE INVENTION 0006 It has now been found that cosmetic and pharmaceutical compositions containing one or more cosmetically or pharmaceutically effective agents, such as anti-inflammatory agents, steroids, vitamins, anti-aging agents, sunscreens, anti-microbial agents, psoriasis-treating agents, acne-treating agents, and dandruff-treating agents, are advantageously coadministered with one or more oxy group-bearing aromatic aldehydes to provide effective topical agents for the treatment of inflammation, skin-thinning, loss of elasticity of the skin, wrinkles, itching, burning, and/or redness, and the like. 0007 As defined herein, an oxy group-bearing aromatic aldehyde is an aromatic aldehyde bearing at least one R3OR2-oxy substituent on its aromatic ring, wherein R2 is a carbon-oxygen single bond or a straight chain or branched chain alkylene and R3 is a straight chain or branched chain alkyl, a cycloalkyl, an alkcycloalkyl, an alkenyl, or an aralkyl. At times herein, this component is referred to as the aldehyde, or the like. 0008 The present invention uses these aromatic aldehydes in combination with another active pharmaceutical or cosmetic agent, such as anti-inflammatory agents, steroids, vitamins, anti-aging agents, sunscreens, anti-microbial agents, psoriasis treating agents, acne-treating agents, and dandruff treating agents. These aldehyde/drug combination compositions are useful in topical pharmaceutical compositions and cosmetic compositions to treat dermatological diseases, such as Rosaceae, psoriasis, and the like, and other dermatological conditions including to inflammation, skin-thinning, loss of elasticity of the skin, wrinkles, itching, burning, and/or redness. In addition these aldehyde/drug combination compositions may show synergistic effects. 0009 In one of its composition aspects, this invention is directed to topical pharmaceutical and cosmetic compositions containing a pharmaceutically-acceptable cosmetic or topical carrier and a combination of one or more cosmetically or pharmaceutically effective agents, such as anti-inflammatory agents, steroids, vitamins, anti-aging agents, sunscreens, anti-microbial agents, psoriasis-treating agents, acne-treating agents, and dandruff-treating agents, and one or more oxy group-bearing aromatic aldehydes. These aromatic aldehydes include materials of Formula I, as well as protected versions, that is, acetals as in Formula II and hemiacetals as in Formula III: 1

0010 wherein 0011 R1 is a carbon-carbon single bond or a straight chain or branched chain alkylene; 0012 R2 is a carbon-oxygen single bond, or a straight chain or branched chain alkylene; 0013 R3 is a straight chain or branched chain alkyl, a cycloalkyl, an alkcycloalkyl, an alkenyl, an aryl or an aralkyl; 0014 each R4 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkcycloalkyl, cycloalkyl, alkoxy, alkcycloalkoxy, cycloalkoxy, acyl, acyloxy and halogen; and 0015 each R5 independently alkyl, or in the case of the acetals of Formula II the two R5s together with the atoms to which they are attached form a heterocycloalkyl. 0016 In another aspect, this invention is directed to methods for treating a patient having a medical or cosmetic condition, such as inflammation, skin-thinning, loss of elasticity of the skin, wrinkles, itching, burning, and/or redness, and the like, which method comprises topically administering to said patient a pharmaceutical composition comprising a pharmaceutically or cosmetically acceptable topical carrier and an effective dermatological condition- or disease-treating amount of a combination of one or more compounds of Formula I, II and III above and one or more of the additional agents, such as anti-inflammatory agents, steroids, vitamins, anti-aging agents, sunscreens, anti-microbial agents, psoriasis-treating agents, acne-treating agents, and dandruff-treating agents.

DETAILED DESCRIPTION OF THE INVENTION

BRIEF DESCRIPTION OF THE DRAWING 0017 FIG. 1: A schematic diagram illustrating inflammatory processes in the skin and showing the relationship of inflammation to the release of various proteins. 0018 FIG. 2: A repeat of FIG. 1 illustrating those inflammatory processes which are effectively treated using the present invention. 0019 FIG. 3 and FIGS. 4A and 4B: Bar graphs which show the effects of aldehydes employed in the compositions of this invention on interleukin 1 (IL-1)-induced prostaglandin E2 (PGE2) expression in dermal fibroblasts. 0020 FIG. 5: A bar graph which shows the effects of aldehydes employed in the compositions of this invention on tetradecanoyl phorbol acetate (TPA)-induced PGE2 expression in keratinocytes. 0021 FIG. 6: A table shows the effects of aldehydes employed in the compositions of this invention and other related compounds on expression levels of varius proteins in fibroblasts challenged with IL-1 or UV light. 0022 FIG. 7: A table which shows the effects of aldehydes employed in the compositions of this invention and other related compounds on expression levels of varius proteins in keratinocytes challenged with TPA or UV light. 0023 FIGS. 8A, 8B, 9A, 9B, 10A, 10B, 11A and 11B: Bar graphs of data tabulated in FIG. 6. 0024 FIGS. 12A, 12B, 13A, 13B, 14A and 14B: Bar graphs of data tabulated in FIG. 7. 0025 FIGS. 15A and 15B: Bar graphs of data obtained in an in vivo test of the lotion formulation of Example 9.

DEFINITIONS 0026 When describing the aromatic oxy group-bearing aldehyde compounds and the at least one other cosmetic and pharmaceutical agent, such as anti-inflammatory agents, steroids, vitamins, anti-aging agents, sunscreens, anti-microbial agents, psoriasis-treating agents, acne-treating agents, and dandruff-treating agents, employed in the cosmetic and pharmaceutical compositions and methods of this invention, the following terms have the following meanings: 0027 Aromatic aldehyde refers to compounds that contain an aryl ring and an aldehyde group or an aldehyde group protected as an acetal or hemiacetal pendent from the ring. 0028 Acyl refers to the group C(O)R where R is hydrogen, alkyl or aryl. When R is hydrogen this is a formyl, when R is CH3 this is acetyl. 0029 Acyloxy refers to the group O-Acyl. 0030 Alkyl refers to monovalent saturated aliphatic hydrocarbon groups preferably having from 1 to about 20 carbon atoms, more preferably from 1 to 12, even more preferably 1 to 8 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, n-octyl, tert-octyl and the like. The term lower alkyl refers to alkyl groups having 1 to 6 carbon atoms and especially 1 to 4 carbon atoms. 0031 Substituted alkyl refers to an alkyl group, preferably of from 1 to about 20 carbon atoms, having from 1 to 5 substituents, and preferably 1 to 3 substituents, selected from the group consisting of alkoxy, cycloalkyl, cycloalkoxy, acyl, aminoacyl, amino, aminocarbonyl, cyano, halogen, hydroxyl, carboxyl, keto, thioketo, alkoxycarbonyl, thiol, thioalkoxy, aryl, aryloxy, nitro, OSO3H, SO-alkyl, SO-substituted alkyl, SO-aryl, SO2-alkyl, SO2-substituted alkyl, SO2-aryl, and mono- and di-alkylamino, mono- and di-arylamino, and unsymmetric di-substituted amines having different substitutents selected from alkyl, substituted alkyl and aryl, and where appropriate, pharmaceutically acceptable salts thereof. 0032 Alkenyl refers to monovalent unsaturated aliophatic hydrocarbon groups having from 1 to 20 carbon atoms and preferably 1 to 6 carbon atoms and 1 to 2 and especially 1 olefinic unsaturation. 0033 Alkylene refers to divalent saturated aliphatic hydrocarbon groups preferably having from 1 to 20 carbon atoms and more preferably 1 to 6 carbon atoms which can be straight chain or branched. This term is exemplified by groups such as methylene (CH2), ethylene (CH2CH2), the propylene isomers (e.g. CH2CH2CH2 and CH(CH3)CH2) and the like. 0034 Alkcycloalkyl refers to -alkylene-cycloalkyl groups preferably having from 1 to 20 carbon atoms in the alkylene moiety and from 3 to 8 carbon atoms in the cycloalkyl moiety. Such alkcycloalkyl groups are exemplified by CH2-cyclopropyl, CH2-cyclopentyl, CH2CH2-cyclohexyl, and the like. 0035 Alkcycloalkoxy refers to O-alkylene-cycloalkyl groups preferably having from 1 to 20 carbon atoms in the alkylene moiety and from 3 to 8 carbon atoms in the cycloalkyl moiety. Such alkcycloalkyl groups are exemplified by OCH2-cyclopropyl, OCH2-cyclopentyl, OCH2CH2-cyclohexyl, and the like. 0036 Alkoxy refers to the group alkyl-O. Preferred alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentyloxy, n-hexyloxy, 1,2-dimethylbutoxy, and the like. 0037 Alkoxycarbonyl refers to the group C(O)OR where R is alkyl. 0038 Aminocarbonyl refers to the group NRC(O)R where each R is independently hydrogen or alkyl. 0039 Aminoacyl refers to the group C(O)NRR where each R is independently hydrogen or alkyl. 0040 Aryl refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g. phenyl) or multiple condensed rings (e.g. naphthyl or anthryl). Preferred aryls include phenyl, naphthyl and the like. Unless otherwise constrained by the definition for the individual substituent, such aryl groups can optionally be substituted with from 1 to 3 substituents selected from the group consisting of alkyl, alkoxy, alkaryloxy, alkenyl, alkynyl, amino, aminoacyl, aminocarbonyl, alkoxycarbonyl, aryl, carboxyl, cycloalkoxy, cyano, halo, hydroxy, nitro, trihalomethyl, thioalkoxy, and the like, and where appropriate, pharmaceutically acceptable salts thereof. 0041 Aralkyl refers to the group-alkylene-aryl groups and is most typically benzyl. 0042 Aryloxy refers to O-aryl groups wherein aryl is as defined above. 0043 Carboxyl refers to the group C(O)OH. 0044 Cyano ref to the group CN. 0045 Cycloalkyl refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, including fused and bridged ring systems, which can be optionally substituted with from 1 to 3 alkyl groups. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like. 0046 Cycloalkoxy refers to O-cycloalkyl groups. Such cycloalkoxy groups include, by way of example, cyclopentyloxy, cyclohexyloxy and the like. 0047 Cosmetically and pharmaceutically effective agents and like terms refer to anti-inflammatory agents, steroids, vitamins, anti-aging agents, sunscreens, anti-microbial agents, psoriasis-treating agents, acne-treating agents, dandruff-treating agents, agents to treat inflammation, agents to treat skin-thinning, agents to treat loss of elasticity of the skin, agents to treat wrinkles, agents to treat itching, agents to treat burning, agents to treat redness, and the like. 0048 Isolated, when used to define the state of purity of the aromatic aldehyde compounds used in the practice of this invention, means that the aromatic aldehyde has been substantially freed of (i.e. at least about 90% and especially at least about 95% freed of) or separated from related feedstocks, co-products, or in the case of naturally-occurring mixtures, related materials with which the aldehyde appears in nature. 0049 Pharmaceutically-acceptable topical carrier and equivalent terms refer to an inactive liquid or cream vehicle capable of suspending or dissolving the aromatic aldehyde and anti-inflammatory agent, steroid, vitamin, anti-aging agent, sunscreen, anti-microbial agent, psoriasis-treating agent, acne-treating agent or dandruff-treating agent and having the properties of being nontoxic and noninflammatory when applied to the skin. This term is specifically intended to encompass carrier materials approved for use in topical cosmetics. Representative carriers include water, oils, both vegetable and mineral, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, penetration enhancers, and the like. Their formulation is well known to those in the art of cosmetics and topical pharmaceuticals. Additional information concerning carriers can be found in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pa., which is incorporated herein by reference. 0050 Therapeutically effective dose refers to a dose of a composition of this invention which, when applied topically to the skin of a patient afflicted with a dermatologic or other cosmetic or medical condition, or when administered by another route, results in an observable improvement in the patient's condition. 0051 Topical, when used to define a mode of administration, refers to a material that is administered by being applied to the skin. 0052 Topically effective refers to a material that, when applied to the skin, produces a desired pharmacological result either locally at the place of application or systemically as a result of transdermal passage of an active ingredient in the material. 0053 The Oxy Group-Bearing Aromatic Aldehydes 0054 The formulations of the present invention comprise oxy group-bearing aromatic aldehydes compounds of Formula I as well as their acetal and hemiacetal equivalents shown in Formulas II and III. At this time, the base aldehydes of Formula I are preferred. 0055 Preferably, in the aromatic aldehyde compounds of Formula I above, R1 is selected from the group consisting of a carbon-carbon single bond, methylene and ethylene. More preferably, R1 is a carbon-carbon single bond. 0056 Preferably, R2 is selected from the group consisting of a carbon-carbon single bond, methylene and ethylene. More preferably, R2 is a carbon-carbon single bond. 0057 Preferably, R3 is a 2 to 6 carbon alkyl. 0058 The four R4s are most commonly hydrogen, alkyl or alkoxy. In this case, generally at least about two of the R4s are hydrogen. 0059 Preferably, each R5 is independently alkyl, or in the case of the acetals of Formula II, the two R5s together with the atoms to which they are attached form a heterocycloalkyl. More preferably each of the R5s together with the atoms to which they are attached form 1,4-dioxacyclopentanyl or a substituted 1,4-dioxacyclopentanyl. 0060 An especially preferred group of compounds of Formula I are those in which R1 is a carbon-carbon single bond; R2 is a carbon-oxygen single bond located in the 4 position on the aromatic ring relative to the aldehyde functionality, R3 is a 2 to 6 carbon alkyl and at least two R4s are each hydrogen. 0061 In another of its preferred composition aspects, this invention is directed to cosmetic and pharmaceutical compositions comprising a suitable carrier and at least one additional cosmetically or pharmaceutically effective agent, such as an anti-inflammatory agent, steroid, vitamin, anti-aging agent, sunscreen, anti-microbial agent, psoriasis-treating agent, acne-treating agent and/or dandruff-treating agent and one or more of the following oxy group-bearing aromatic aldehyde compounds: 2-ethoxybenzaldehyde, 4-allyloxy-benzaldehyde, 4-ethoxybenzaldehyde, propoxybenzaldehyde, 4-butoxybenzaldehyde, 4-pentyloxybenzaldehyde, and 4-hexyloxybenzaldehyde. 0062 The aromatic aldehydes are generally employed as at least one isolated compound mixed with at least one additional cosmetically or pharmaceutically effective agent, such as an anti-inflammatory agent, steroid, vitamin, anti-aging agent, sunscreen, anti-microbial agent, psoriasis-treating agent, acne-treating agent and/or dandruff-treating agent and a suitable carrier. 0063 The Additional Cosmetically or Pharmaceutically Effective Agent 0064 The following are examples of the cosmetic and pharmaceutical agents described above for use with the oxy group-bearing aromatic aldehydes. These agents are known compounds and are readily available commercially. 0065 Anti-inflammatory agents include, but are not limited to, bisabolol, mentholatum, Aloe, hydrocortisone, and the like. 0066 Steroids include, but are not limited to, prednisone, hydrocortisone and the like. 0067 Vitamins include, but are not limited to, Vitamin B, Vitamin E, Vitamin A, Vitamin D, and the like and vitamin derivatives such as Tazorac, Dovenex, and the like. 0068 Anti-aging agents include, but are not limited to, niacinamide, retinol and retinoid derivatives, AHA, Ascorbic acid, lipoic acid, coenzyme Q10, beta hydroxy acids, salicylic acid, copper binding peptides, dimethylaminoethyl (DAEA), and the like. 0069 Sunscreens and or sunburn relief agents include, but are not limited to, PABA, jojoba, aloe, padimate-O, methoxycinnamates, proxamine HCl, lidocaine and the like. Sunless tanning agents include, but are not limited to, dihydroxyacetone (DHA). 0070 Hair-loss prevention or treatment agents include, but are not limited to, Minoxidil, alpha reductase inhibitors, such as fenestride and polysorbate 80, and the like. Immunosupressents, such as steriods, are also thought to stimulate hair growth and are contemplated for use in the present invention. 0071 Anti-microbial agents include, but are not limited to, clotrimazole, miconazole nitrate, terbinafine HCL, and the like. 0072 Psoriasis-treating agents and/or acne-treating agents and/or dandruff-treating agents include, but are not limited to, salicylic acid, benzoyl peroxide, coal tar, selenium sulfide, zinc oxide, pyrithione (zinc and/or sodium), Dovenex, Tazorac, and the like. 0073 Also contemplated are agents for treatment of dermatitis, itch, poison ivy, and the pain associated with these conditions. These agents include Camphor, phenol and the like. 0074 In addition vasoconstrictors like phenylephrine, and the like, are useful in the present combination products. These agents maybe used for the treatment of rosacea. 0075 General Synthetic Procedures 0076 The aromatic aldehydes employed in the compositions and methods of this invention are either known compounds or are compounds that can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. 0077 For example, such compounds are readily prepared by acylation of the corresponding aryl compound with the appropriate acyl halide under Friedel-Crafts acylation reaction conditions. Additionally, the formyl compounds, i.e. those compounds where R4 is hydrogen, can be prepared by formulation of the corresponding aryl compound using, for example, a disubstituted formamide, such as N-methyl-N-phenylformamide, and phosphorous oxychloride (the Vilsmeier-Haack reaction), or using Zn(CN)2 followed by water (the Gatterman reaction). Numerous other methods are known in the art for preparing such aryl carbonyl compounds. Such methods are described, for example, in I. T. Harrison and S. Harrison, Compendium of Organic Synthetic Methods, Wiley, New York, 1971, and references cited therein. 0078 Certain aromatic aldehyde compounds of Formula I can also be prepared by alkylation of the corresponding aryl hydroxy compound (e.g. 4-hydroxybenzaldehyde and the like). This reaction is typically conducted by contacting the aryl hydroxy compound with a suitable base, such as an alkali or alkaline earth metal hydroxide, fluoride or carbonate, in a inert solvent, such as ethanol, DMF and the like, to deprotonate the hydroxyl group. This reaction is generally conducted at about 0 C. to about 50 C. for about 0.25 to 2 hours. The resulting intermediate is then reacted in situ with about 1.0 to about 2.0 equivalents of an alkyl halide, preferably an alkyl bromide or iodide, at a temperature of from about 25 C. to about 100 C. for about 0.25 to about 3 days. 0079 Additionally, various aromatic aldehydes of Formula I can be prepared by reduction of the corresponding aryl nitriles. This reaction is typically conducted by contacting the aryl nitrile with about 1.0 to 1.5 equivalents of a hydride reducing agent, such as LiAlH(OEt)3, in an inert solvent such as diethyl ether, at a temperature ranging from about 78 to about 25 C. for anout 1 to 6 hours. Standard work-up conditions using aqueous acid then provides the corresponding aryl aldehyde. 0080 The aromatic aldehydes of Formula II and III employed in the compositions and methods are either known compounds or compounds that can be prepared from known compounds by conventional procedures. The hemiacetals can be formed by either acid or base catalyzed reaction of the corresponding aldehyde with and alcohol. If a single equivalent of the alcohol is added to the carbonyl, the hemiacetal is formed. Addition of 2 equivalents of an alcohol to the carbonyl produces the acetal. Acetal formation is acid catalyzed and is typically conducted by adding 1 mol of aldehyde and a 0.1 mol of aldehyde and a 0.1 mole of CaCl2 to 1.9 mol of ethanol. The reaction mixture is held at room temperature for 1 to 2 days. Standard work up conditions provide the acetal protected aromatic aldehyde. 0081 Pharmaceutical and Cosmetic Compositions and Their Use 0082 The compositions containing a combination of oxy group-bearing aromatic aldehydes and anti-inflammatory agent, steroid, vitamin, anti-aging agent, sunscreen, anti-microbial agent, psoriasis-treating agent, acne-treating agent and/or dandruff-treating agent are administered in the form of a pharmaceutical or cosmetic composition. Such compositions can be prepared in manners well known in the pharmaceutical and cosmetic arts and comprise at least one active compound. 0083 Generally, the compositions of this invention are administered in a cosmetic amount or a therapeutically effective dose. The amount of the compound actually administered in therapeutic settings may typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. In cosmetic settings the amount to be applied is selected to achieve a desired cosmetic effect. 0084 The cosmetic and pharmaceutical compositions of this invention are to be administered topically. In a primary application, this leads to the aldehyde and the other active agent working upon and treating the skin. Alternatively the topically applied active agents can be delivered systemically by transdermal routes. 0085 In such compositions, the aromatic aldehyde compound is usually aminor component (from about 0.001 to about 20% by weight or preferably from about 0.01 to about 10% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form. 0086 In such compositions the additional cosmetically or pharmaceutically effective agent, such as the anti-inflammatory agent, steroid, vitamin, anti-aging agent, sunscreen, anti-microbial agent, psoriasis-treating agent, acne-treating agent and/or dandruff-treating agent, and the like, is usually a minor component (from about 0.001 to about 20% by weight or preferably from about 0.01 to about 10% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form. 0087 Topical cosmetic forms and topical pharmaceutical dosing forms can include lotions, shampoos, soaks, gels, creams, ointments and pastes. Lotions commonly employ a water and oil base. Gels are semi-solid emulsions or suspensions. Creams generally contain a significant proportion of water in their base while ointments and creams are commonly more oily. 0088 Liquid forms, such as lotions suitable for topical administration or suitable for cosmetic application, may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, thickeners, penetration enhancers, and the like. Solid forms such as creams or pastes or the like may include, for example, any of the following ingredients, water, oil, alcohol or grease as a substrate with surfactant, polymers such as polyethylene glycol, thickeners, solids and the like. Liquid or solid formulations may include enhanced delivery technologies such as liposomes, microsomes, microsponges and the like. 0089 The above-described components for liquid, semisolid and solid topical compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pa., which is incorporated herein by reference. 0090 When pharmaceutical compositions are to be administered systemically by transdermal routes, they typically are employed as liquid solutions or as gels. In these settings the concentration of active aldehyde ranges from about 0.1% to about 20%, and preferably from about 0.1% to about 5%, of the composition with the remainder being aqueous mixed or nonaqueous vehicle, such as alcohols and the like, suspending agents, gelling agents, surfactant, and the like. Examples of suitable such materials are described below. 0091 The aldehyde-containing compositions of this invention can also be administered in sustained release transdermal forms or from transdermal sustained release drug delivery systems. A description of representative sustained release materials can be found in the incorporated materials in Remington's Pharmaceutical Sciences. 0092 The following formulation examples illustrate representative cosmetic and pharmaceutical compositions of this invention. The present invention, however, is not limited to the following pharmaceutical compositions. 0093 Formulation 1Sunburn Gel 0094 A compound of Formula I, II or III (125 mg), lidocaine (25 mg), aloe (250 mg) are blended with a previously made (5 mL) made up of ethanol, transcutol (ethoxydiglycol), water, propylene glycol, dimethylisosorbide, and hyrdoxypropyl cellulose (HPC), as a thickener. 0095 Formulation 2Exfolient Skin-Treating Cream 0096 A commercial mineral oil-water cold cream base is obtained. To 100 grams of this base, 1.0 gram of a compound of Formula I, II or III and 2.5 grams of niacinamide is added with continuous mixing and stirring to yield a cosmetic or pharmaceutical cream composition. 0097 This composition includes the following: deionized water (57.6% by weight); salicylic acid (2.0%); glycerin (4.0%); phenonip (1.0%); propylene glycol (5.0%); transcutol (3.2%); jojoba Oil (3.5%); isocetyl alcohol (2.0%); isocetyl stearate (3.5%); mineral oil (3.0%): 4-ethoxybenzaldehyde (1.0%); isostearyl palmitate (3.0%); PEG-7 glyceryl cocoate (2.0%); Glycereth-7 (2.0%); POLYSORBATE-20 (0.2%); cetyl ricinoleate (1.0%); glyceryl stearate/PEG-100 stearate (4.0%); and SEPIGEL (2.0%). 0098 Utility and Dosing 0099 The compositions and methods of this invention can be used topically to treat cosmetic and pharmaceutical conditions. These conditions range from well-characterized medical conditions, such as psoriasis, acne, eczema, seborrheic dermatitis, and the like, to more appearance related states such as redness (from sunburn, or a reaction to the other active ingredient in the combination product), wrinkles, a desire for sunless tanning, or skin dryness and the like. 0100 In these applications the cosmetic and pharmaceutical compositions are administered topically to achieve a desired cosmetic effect or a topical therapeutic effect. 0101 In these uses the dose levels or application levels can be expressed in terms of the amount of active aromatic aldehyde and other active ingredients delivered to the skin. For example, 1 to about 5 doses or applications per day, each containing from about 0.001 g to about 1 gram of active aldehyde and similar amounts of the other active ingredients. 0102 Alternatively, dose levels can be expressed in terms of the volume of formulated composition administered. For example, 1 to about 5 doses or applications per day, each containing from about 1 to about 30 grams of composition containing from about 0.01% to about 10% by weight of active aldehyde and especially from 0.02% to about 8% by weight, and similar amounts of the other active ingredients. 0103 Additionally, since the aromatic aldehydes have been discovered to effectively inhibit the release of cytokines such a IL-1, such compounds are useful for treating diseases or conditions characterized by an overproduction or a dysregulated production of cytokines, particularly IL-1. Elevated levels of IL-1 and other cytokines are associated with a wide variety of inflammatory conditions, including rheumatoid arthritis, septic shock, erythema, nodosum, leprosy, septicemia, adult respiratory distress syndrome (ARDS), inflammatory bowel disease (IBD), uveitis, damage from ionizing radiation and the like. 0104 The relationships between these cytokines and related materials and the inflammatory processes are described in more detail below at Biology and Testing. 0105 In the case of transdermal administration to treat such inflammatory conditions, one can administer a quantity of composition to a surface area of skin suitable to achieve an active aldehyde concentration in the systemic bloodstream of from about 0.5 to about 1000 micromolar and especially from about 1 to about 500 micromolar. 0106 Biology and Testing 0107 The examples include a number of in vitro studies to investigate the ability of the aldehydes used in these combination products to block various inflammatory processes in the skin. For these studies primary human keratinocytes and dermal fibroblast cell strains have been used as well as THP-1 monocytes and the Jurkat T-cell derived cell line. The in vitro experiments used to assess the anti-inflammatory activities of the aldehydes were selected on the basis of current knowledge about the skin inflammatory process. FIG. 1 depicts the events involved in cutaneous inflammation. 0108 Inflammation in the skin is characterized by itching, pain, redness, swelling and, frequently, rough and flaky skin. These symptoms result from changes in blood flow to the site of inflammation, increased vascular permeability, the migration of immune cells from the circulation into the tissue, and the release of soluble mediators including cytokines, prostaglandins and chemokines. Skin inflammation can be triggered by: 1) infection caused by bacteria, parasites, fungi, or viruses, 2) injury resulting from physical trauma including burns, UV and ionizing radiation, 3) contact with chemical irritants, 4) exposure to a foreign body such as an allergen which triggers an immune response, and 5) in some cases, the additional agents present in the combination products. 0109 Inflammation can be characterized as acute or chronic. Acute inflammation can result from exposure to UV radiation (UVR), ionizing radiation or contact with chemical irritants and allergens. In contrast, chronic inflammation results from a sustained immune cell mediated inflammatory response. Acute inflammatory responses are typically resolved within 1 to 2 weeks with little accompanying tissue destruction. Chronic inflammatory responses, however, are long-lasting because the antigen that triggered the response persists in the skin. This leads to continued recruitment of immune cells into the tissue, particularly T lymphocytes, which then produce and secrete high levels of many inflammatory mediators. Chronic inflammation leads to significant and serious tissue destruction. 0110 Regardless of the stimulus that triggers either an acute or chronic cutaneous inflammatory response, the initial events are similar and are shown in FIGS. 1 and 2. Triggering stimuli, such as UV radiation, induce keratinocytes in the to produce various cytokines including the key inflammatory cytokine, Interleukin-1 (IL-1). These cells also produce Tumor Necrosis Factor (TNF-) and prostaglandin E2 (PGE-2). PGE-2 causes vasodilation of blood vessels near the site of injury and also increases the sensitivity of sensory nerve endings resulting in the sensation of itching and pain. The principal action of TNF- is to increase the production of adhesion molecules on the surface of endothelial cells lining the blood vessels. These adhesion molecules act as anchors within the blood vessel allowing immune cells moving through the circulation to attach to the endothelium, an event that can lead to the diapedsis (movement) of these cells from the circulation and into the tissue. IL-1 produced by keratinocytes binds to specific receptors on fibroblasts within the dermis and activates signaling pathways that lead to the induction of many pro-inflammatory genes, such as those for COX-2, IL-8 and IL-6. IL-1 also binds to specific receptors on mast cells resulting in the production and secretion of histamine (which also increases nerve ending sensitivity), cytokines and other inflammatory mediators. In addition to responding to keratinocyte-derived IL-1, fibroblasts can also be directly activated by the triggering stimulus (e.g. UVR) and this further stimulates the expression of pro-inflammatory genes resulting in the production of PGE-2, the chemokine IL-8, as well as collagenase-1 (MMP-1). IL-8 stimulates diapedsis (chemotaxis, movement) of neutrophils, monocytes and ultimately lymphocytes from the endothelial cells where they have attached as a result of the TNF- induced increase in adhesion molecules. Once in the tissue, neutrophils and monocytes produce additional cytokines (IL-1, IL-2), and chemokines including monocyte chemotactic protein (MCP-1), a potent chemokine that accelerates the movement of monocytes into the tissue and helps transform them into macrophages. Mature macrophages in turn produce a variety of matrix metalloproteinases (MMPs) that degrade extracellular matrix proteins and thus reduce the strength, elasticity and thickness of the skin. 0111 If the inflammatory response is maintained by the continued presence of an antigen in the skin as is the case with chronic and destructive cutaneous diseases such as psoriasis and atopic dermatitis, the persistence of the antigen causes T-lymphocytes to enter the tissue site and become activated. This activation leads to the production of cytokines such as TNF-, monocyte chemotactic protein-I (MCP-1), IL-8, IL-12, and interferon- (INF-). Released IL-12 causes the T-lymphocytes to proliferate rapidly and to produce a wide range of cytokines, growth factors and other inflammatory mediators. These released products further activate macrophages, recruit monocytes, increase tissue destruction and cause accelerated and uncontrolled growth of skin cells, particularly keratinocytes. The result is pronounced skin inflammation with redness, pain, itching and scaling of the skin as the keratinocytes move rapidly to the surface and flake off. Further, the rapid shedding of keratinocytes at the surface compromises the barrier function of the stratum corneum resulting in water loss and dry skin. 0112 A common finding in inflammation is that cells in the skin respond to inflammatory stimuli by activating either one of two intracellular signaling pathways (or in some cases both pathways). These pathways are commonly referred to as the Stress Activated Kinase (SAK) pathway and the NF-kB pathway. The SAK pathway leads to the activation of the AP-1 transcription factor, which then binds to and activates several inflammatory genes including COX-2, IL-6 and MCP-1. Activation of the NF-kB pathway results in NF-kB protein translocation to the nucleus and activation of NF-kB driven inflammatory genes such as IL-8, MMP-1, TNF- and the adhesion molecule, VCAM-1. Interestingly, many inflammatory genes including IL-1 have promoter elements that bind both AP-1 and NF-kB transcription factors and are thus regulated to some extent by both signaling pathways. The Cutanix screening assays are designed to determine which pathway is blocked by the compound under investigation, or if both pathways are effectively inhibited. A compound with the capacity to block the transcription of inflammatory genes regulated by each of these pathways will likely provide significant anti-inflammatory effects when applied topically. For each putative anti-inflammatory compound under consideration the initial screening program concentrates on the following target sites for intervention: 0113 1. Inhibiting the production of IL-1 and PGE-2 in UVR or Tetradecanoyl Phorbol Acetate-treated keratinocytes. 0114 2. Inhibiting the production of PGE-2 in UVR treated dermal fibroblasts. 0115 3. Inhibiting the induction of PGE-2 in IL-1 treated fibroblasts. 0116 Because one of the most common activators of skin inflammation is sunlight, specifically UVB radiation, the determination of a compound's ability to block the induction of pro-inflammatory PGE-2 by UVR in both keratinocytes and fibroblasts represents a logical first step in the screening process. In addition, because skin inflammation is often triggered by contact with chemical irritants or allergens, the use of TPA, which is known to trigger an inflammatory response in the skin, provides an additional model for the analysis of anti-inflammatory activities of test compounds. Finally, because IL-1 is one of the most important mediators and propagators of inflammation and is rapidly induced by an inflammatory stimulus, such as UVR, determining the ability of a potential anti-inflammatory compound to block either the production or action of IL-1 is a critically important initial screening study. As shown in FIGS. 1 and 2, by blocking IL-1 production from keratinocytes, not only is the activation of fibroblasts suppressed but the activation of mast cells is also blocked thus preventing the release of histamine and other inflammatory mediators. Furthermore, inhibition of IL-1 production in the skin would prevent the activation of a large number of inflammatory genes that are stimulated solely by IL-1. These include COX-2, MMP-1, and a variety of cytokine and chemokine genes. 0117 For all of the initial screening studies described herein, cells in culture are exposed to the appropriate agonist, (i.e. UVR, TPA or IL-1) and then incubated in medium for 24 or 48 hours in the presence or absence of the compound under investigation. At 24 and 48-hour time points, medium from the cells is removed and assayed for a number of inflammatory mediators by ELISA. 0118 Only primary keratinocyte and fibroblast cell strains were used, not immortalized cell lines, for the screening studies. The use of normal cells from the skin increases the probability that results from in vitro studies will be predictive of effects of a given compound when applied topically. 0119 Aldehydes that are found to completely (100%) suppress PGE-2 induction at a concentration of 100 micromolar or less are then subjected to more demanding response studies including the following sequence of experiments: 0120 1. Assessment by ELISA of a compound's ability to block a variety of UVR, TPA, or IL-1 induced inflammatory mediators in keratinocytes and fibroblasts including IL-6, TNF-, IL-8, and MMP-1. 0121 2. 2. Assessment by ELISA of a compound's ability to block the production and secretion of inflammatory mediators by monocytes (THP-1 monocyte line) stimulated by lipopolysaccharide (LPS) and by T lymphocytes (Jurkat cells) stimulated with an antibody ligand that activates the cells. 0122 3. The use of RPA (ribonuclease protection analysis) to determine if a compound is acting at the gene level to suppress the activity of specific inflammatory genes stimulated by exposure of cells to various agonists including UVR, IL-1, TPA, or LPS (lipopolysaccharide). Cutanix has developed a customized RPA cocktail for keratinocytes, fibroblasts, T-cells, and monocytes to simultaneously measure the expression of cell-type specific inflammatory genes in cells stimulated with UVR, IL-1, TPA or LPS in the presence or absence of the compound under investigation. 0123 4. The use of microarray gene analysis to simultaneously examine the effect of any compound on the expression of more than 5,500 genes specific for cells present in the skin. The gene arrays used were purchased from Research Genetics and provide read-outs on genes known to be expressed in the skin. 0124 The aldehydes can suppress a number of pro-inflammatory mediators and FIG. 2 identifies some of the events that are likely inhibited by the aldehydes in vivo (shown by the circled X).

EXAMPLES 0125 The following examples are provided to further describe the invention and are not intended as limitations on the scope of the invention which is defined by the appended claims.

Example 1 0126 An initial in vitro experiment was conducted to demonstrate the activity of the aromatic aldehyde, 4-ethoxybenzaldehyde, (4-EB) as a component of a topically-administered pharmaceutical or cosmetic combination product of this invention. 0127 For this experiment, human skin fibroblasts were seeded into 12 well culture dishes at a density of 80,000 cells/wells in tissue culture medium and left overnight to attach to the dish. The next day, medium was removed and replaced with fresh medium containing either 1% ethanol as a diluent control, IL-1 at a concentration of 500 picograms/ml, or IL-1 plus 4-EB at either 250 M or 500 M. Cells were incubated for an additional 24 hours and at this time, the medium was removed and assayed by ELISA for the presence of PGE-2 in the culture medium. The results show that IL1 caused a 17.8 fold increase in PGE-2 (control727 pg/106 cells: IL-112,976 pg/106 cells). However, cells treated with either concentration of 4-EB showed a complete inhibition of the IL-1 induction of PGE-2. The percent inhibitions are as follows: 4-EB, 100%, 6% and 10% at 50 M, 10 M and 1 M.

Example 2 0128 Subsequent studies were carried out to determine the dose-response of human skin fibroblasts to 4-EB. 4-EB completely blocked the IL-1 induction of PGE-2 at 100 M, blocked 82% of the PGE-2 induction at 50 M, and blocked 35% at a concentration as low as 10 M. The results of the study are provided graphically in FIG. 3A.

Example 3 0129 Similar in vitro studies as those described in Example 1 were run using human skin keratinocytes. The experimental set up was the same as described for Example 2, but replacing IL-1 with tetradecanoyl phorbol acetate (TPA) at a concentration of 32 nM as the agonist. The percent inhibitions are as follows: 4-EB, 94.9% and 79.9% at 1001M and 50 M.

Example 4 0130 Subsequent in vitro experiments were conducted to demonstrate the activity of other aromatic aldehydes compared to the 4-ethoxybenzaldehyde, (4-EB) as topically-administered pharmaceuticals and cosmetics. The compounds tested were 2-ethoxybenzaldehyde (2-EB), 3-ethoxybenzaldehyde (3-EB), and 4-methoxybenzaldehyde (4 MB). 0131 For this experiment, human skin fibroblasts were seeded into 12 well culture dishes at a density of 80,000 cells/wells in tissue culture medium and left overnight to attach to the dish. The next day, medium was removed and replaced with fresh medium containing either 1% ethanol as a diluent control, IL-1 at a concentration of 500 picograms/ml, or IL-1 plus one of the compounds under investigation at a concentration of 1, 10, 50 or 100 M. Cells were incubated for an additional 24 hours and at this time, the medium was removed and assayed by ELISA for the presence of PGE-2 in the culture medium. The results show that IL-1 cause a 4 to 22 fold increase in PGE-2. 0132 Percent inhibitions as shown in the detailed results in FIG. 4A) are as follows: 2-EB, 82.9% and 58.9% at 100 M and 50 M; 3-EB, 41.2% and 42.6% at 100 M and 50 M; 4-EB, 81.5% at 100 M. 0133 Concentrations of 10 or 50 M 4 MB did not appear to inhibit the IL-1 induced production of PGE-2 in the fibroblasts. Percent inhibitions as shown in the detailed results of FIG. 4B) are as follows: 4-MB, 13.6% and 16.2% at 50 M and 10 M.

Example 5 0134 Similar in vitro studies as those described in Example 4 were run using human skin keratinocytes. The experimental set up was the same as described for Example 5 but replacing IL-1 with tetradecanoyl phorbol acetate (TPA) at a concentration of 32 nM as the agonist. The compounds tested were 2-ethoxybenzaldehyde (2-EB), and 3-ethoxybenzaldehyde (3-EB) and 4-ethoxybenzaldehyde (4-EB) in concentrations of either 10, 50, or 100 M. The results show that TPA caused a 3.5 fold increase in PGE-2. However, treatment with any of these compounds blocked PGE-2 production by at least 50%. 0135 The percent inhibitions as shown in the detailed results in FIG. 5 are as follows: 2-EB, 83%, 76.6% and 55.2% inhibition at 100 M, 50 M and 10 M; 3-EB, 76.7% and 57.7% at 100 M and 50 M; 4-EB, 94.9% and 79.9% at 100 M and 50 M.

Example 6 0136 In vitro experiments were conducted to demonstrate the activity of a series of aromatic aldehydes as agents in topically-administered pharmaceuticals and cosmetics. The compounds tested and the measured results are tabulated in FIG. 6 and shown graphically in FIGS. 8-11. These data include results for aldehydes of Formula I and also include results for other related compounds. 0137 For this experiment, human skin fibroblasts were seeded into 12 well culture dishes at a density of 80,000 cells/wells in tissue culture medium and left overnight to attach to the dish. The medium was then replaced with PBS for a challenge with either UV-light or with IL-1. After irradiation or introduction of IL-1, the PBS was removed and culture medium containing the appropriate compound (or DMSO for controls) was then added and the cells cultured for an additional 24 hours. At that time, the medium was removed and assayed by ELISA for the presence of PGE-2, IL-1, IL-6, IL-8, or MMP-I in the culture medium. The levels of protein in the conditioned medium were measured and reported as percent relative to diluent controls. 0138 IL-1 Challenge 0139 On the second day, the medium was removed and replaced with fresh medium containing either 1% ethanol as a diluent control, IL-1 at a concentration of 500 picograms/ml, or IL-1 plus one of the compounds under investigation at a concentration of 100, 10, or 1 M. 0140 UV-Light Challenge 0141 On the second day, the medium was removed and replaced with fresh PBS for irradiation. The fibroblasts were then irradiated with 50 mJ of UVB. UVB irradiation was obtained by illuminating the samples with an FS-20 sunlamp through the lids of the multi-well plates in order to filter out the UVC radiation. After irradiation the PBS solution was removed and replaced with a solution containing either 1% ethanol as a diluent control, or one of the aldehyde compounds at a concentration of 100, 10, or 1 M. The cells were incubated for another 24 hours and the medium was then removed for the ELISA assays and the cells were counted.

Example 7 0142 Similar in vitro studies as those described in Example 6 were run using human skin keratinocytes. The experimental set up was the same as described for Example 6. The products assayed by ELISA for the presence of PGE-2, IL-1, IL-6, IL-8, MMP-1 or TNF- in the culture medium. 0143 For the cells challenged by a biochemical agonist, IL-1 was replaced with tetradecanoyl phorbol acetate (TPA) at a concentration of 32 nM. When UV-light was used to challenge the cells, they were exposed to 75 mJof UVB, obtained by illuminating the samples with an FS-20 sunlamp through the lids of the multi-well plates in order to filter out the UVC radiation. 0144 The compounds tested were in concentrations of either 100, 10, or 1 M, and the protein expression levels are reported in percent inhibition relative to control treated cells. The measured percent inhibitions are tabulated in FIG. 7 and shown graphically in FIGS. 12-14.

Example 8 0145 Because of the marked anti-inflammatory effects seen when 4-EB was used in human fibroblast cell culture models, in vivo studies were carried out to determine if topically applied 4-EB could block an inflammatory response in humans. While the details provided herein are for a specific compound, the same tests can be used on any of the aromatic aldehydes of the present invention. 0146 A topical lotion was developed for 4-EB which consists of the following: 1Aqueous phaseDeionized water57.6%(by weight)Niacinamide2.0%Glycerin4.0%Phenonip1.0%Oil phasePropylene glycol5.0%Transcutol3.2%Jojoba Oil3.5%Isocetyl alcohol2.0%Isocetyl Stearate3.5%Mineral Oil3.0%4-ethoxybenzaldehyde1.0%Isostearyl Palmitate3.0%PEG-7 Glyceryl Cocoate2.0%Glycereth-72.0%POLYSORBATE-200.2%Cetyl Ricinoleate1.0%Glyceryl Stearate/PEG-100 Stearate4.0%ThickenerSEPIGEL2.0%

0147 This lotion was then tested by Franz cell percutaneous absorption analysis to determine how much 4-EB could penetrate human skin over a 24 hour period. The lotion formulation above provided a flux rate of 4-EB through human skin of 30-50 micrograms/hour. 0148 This lotion was then tested to determine if it could prevent an inflammatory response when applied topically to human skin. For this study a lab volunteer was irradiated on a quarter sized spot on the inner forearm with 60-80 mJ of UVB light (a sunlamp). This dose was sufficient to cause a highly visible red erythema response. Immediately following irradiation on both arms, one arm was treated with the above 4-EB lotion while the other arm was treated with the same lotion formulation but with no 4-EB. Within 2-6 hours after irradiation the vehicle-treated arm developed a pronounced red erythema response at the site of irradiation while the 4-EB lotion treated spot did not. Even the next day, 14 hours post-irradiation, the spot treated with 4-EB showed no redness. This study demonstrates that topically applied 4-EB has marked anti-inflammatory activity. 0149 In addition to its anti-inflammatory activity, compounds of the present invention, either alone or in combination with other compounds, such as ethyl vanillin, may have anti-aging properties. One of the classical symptoms of skin aging is an increase in collagenase activity in dermal fibroblasts which destroys collagen thereby leading to sagging skin and wrinkles. 0150 Implications of the Results in terms of Potential Uses of the Discovery Anti-Aging 0151 The finding that aromatic aldehydes of the present invention inhibit the activity of inflammatory genes in cultured skin cells and that they can block an inflammatory response in vivo when applied topically suggests wide utility for these compounds in the cosmetic, dermatology and oral drug markets. In the cosmetic market, these compounds when formulated for topical use can be expected to lower chronic sun-induced inflammation, which causes the activation of genes in skin cells that destroy the skin matrix. By inhibiting sun-induced genes such as MMP-I (collagenase), gelatinase, and cytokines IL-1, IL-12, etc. 2-EB, 3-EB and 4-EB will prevent the further breakdown of the skin and thus lessen the production of lines and wrinkles, sagging skin and thinning of skin. It is likely that these aromatic aldehydes will stimulate genes that support the skin matrix such as collagen (studies ongoing). Thus, this product can be used as a skin restorative product for sun-damaged skin. It has its utility in treating actinic keratoses by both preventing their formation and actually reducing the size and number of existing keratoses. 0152 Sun Care Products 0153 The finding that topically applied 4-EB, or any other compound of this invention, can completely prevent the onset of a sunburn by UVB exposure suggests the use of aromatic aldehydes in sun care products including pre-sun, sun-tan lotions, and after-sun products. It is not suggested that the molecules have sun-screen properties (which they probably do to some extent) but that they can actually arrest the progression of a sunburn AFTER the skin has already been exposed to the UV rays of the sun. Although it has been shown that topical application of the product immediately after UVB exposure will prevent the onset of sunburn, it is also possible that application of the product even after the sunburn has appeared may: 1) prevent the continued progression of sunburn, and 2) reverse the redness already present.

Example 9 0154 Rosacea Clinical Study 0155 The 30 subjects with mild to moderate rosacea were treated either with lotion containing 1% w 4-EB (20 subjects) or with a control lotion with the active material removed. The study was randomized and double blinded. During their first visit, patients were evaluated using 4 measurements of disease: 1) erythema, 2) desquamation (peeling), 3) uneven skin tone, and 4) dermatitis. The clinician also provided an Overall Severity score which ranged from 1-6 with 6 being the most severe level of overall disease. Patients were photographed to record the severity of the disease. After evaluation patients were sent home with either the test lotion or the control lotion and told to apply it morning and evening for two weeks. They then returned to the clinic for a two-week evaluation and at that time received more product for an additional 2 weeks. At four weeks, both the clinician and the subjects evaluated the severity of their disease. Digital photographs of the treated areas were also taken. 0156 Of the 30 rosaceae patients that started the study, 28 completed the four-week period. None of the subjects, including those who dropped out, experienced any irritation or other adverse effect from the product. The bar graph of FIG. 15A summarizes the percentage improvement in Overall Severity for the test lotion treated group at 4 weeks. As can be seen, the severity of rosacea decreased in 13/18 subjects (72%). Average improvement amount those respondeing was 68% (49% for all patients). This is a statistically significant result. 0157 The bar graph of FIG. 15B summarizes the percentage improvement in Overall Severity for the control lotion treated group at 4 weeks. As can be seen, the severity of rosacea decreased in 6/10 subjects (60%) but increased in 3/10 (30%). Average overall improvement was 15% which is not a significantly significant result. 0158 The test lotion also achieved another important statistical threshold in the rosacea study. The degree of improvement in the test lotion treated group was significantly better than the degree of improvement in the control treated group (p0.05) using both Wilcoxon and Analysis of Variance statistics. These results are of sufficient quality to meet regulatory standards for drug efficacy and clearly establish the ability of 4-ethoxybenzaldehyde to suppress skin inflammation in humans. 0159 Rosacea is a difficult disease to treat because of the severity of skin inflammation and vasodilation. Considering that a 2% formulation of 4-EB has been shown to be more effective in blocking UV-induced erythema than the 1% formulation used in this clinical study, a higher strength version of the test lotion may provide even greater efficacy in treating rosacea.